Company
Solve Therapeutics
Targeting cancer with best-in-class ADCs
Also known as Solve Therapeutics, Inc
- Business model
- B2B
- Legal name
- Solve Therapeutics, Inc
Claim, correct or request removal
Record updated 29 September 2026
About
Solve is developing novel antibody-drug conjugates (ADCs) with high selectivity and optimized payload delivery enabled by CloakLink™, our proprietary hydrophilic linker system.
Funding snapshot
- Total raised
- $162MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $48.2M2025-11-14
Funding rounds
- Round, 2025
- $48.2M2025-11-14, SEC form D sold, 16 investors
- Round, 2024
- $50.4M2024-12-13, SEC form D sold, 10 investors
- Round, 2021
- $63.5M2021-12-17, SEC form D sold, 11 investors
Products
- Web
- SLV-154
- Web
- SLV-324
Loading relationship preview